MNPR logo

MNPR
Monopar Therapeutics Inc

3,320
Mkt Cap
$375.3M
Volume
202,625.00
52W High
$105.00
52W Low
$28.40
PE Ratio
-28.24
MNPR Fundamentals
Price
$56.08
Prev Close
$57.92
Open
$57.60
50D MA
$57.13
Beta
1.45
Avg. Volume
187,961.48
EPS (Annual)
-$1.85
P/B
2.72
Rev/Employee
$0.00
$343.70
Loading...
Loading...
News
all
press releases
Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen
Wall Street Zen downgraded Monopar Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Brookline Capital Markets Forecasts MNPR Q1 Earnings
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets increased their Q1 2026 EPS estimates for Monopar Therapeutics in a research report...
MarketBeat·4d ago
News Placeholder
HC Wainwright Brokers Reduce Earnings Estimates for MNPR
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2026 EPS estimates for Monopar Therapeutics in a report issued on Monday, March 30th. HC...
MarketBeat·11d ago
News Placeholder
Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)
Chardan Capital reaffirmed a "buy" rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday...
MarketBeat·13d ago
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) announced its earnings results on Friday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of...
MarketBeat·15d ago
News Placeholder
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has been given a consensus rating of "Buy" by the thirteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and two have is...
MarketBeat·18d ago
News Placeholder
Monopar Therapeutics (MNPR) to Release Earnings on Monday
Monopar Therapeutics (NASDAQ:MNPR) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-monopar-therapeutics-inc-stock...
MarketBeat·20d ago
News Placeholder
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) by 86.6% in the 3rd quarter, according to its most recent disclosure with the...
MarketBeat·28d ago
News Placeholder
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Buy" from Brokerages
Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have received an average rating of "Buy" from the thirteen ratings firms that are presently covering the firm, Marketbeat reports...
MarketBeat·1mo ago
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research
BTIG Research reaffirmed a "buy" rating and set a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday...
MarketBeat·2mo ago
<
1
2
...
>

Latest MNPR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.